EA200500406A1 - Активный ингибитор серинпротеазы hcv - Google Patents

Активный ингибитор серинпротеазы hcv

Info

Publication number
EA200500406A1
EA200500406A1 EA200500406A EA200500406A EA200500406A1 EA 200500406 A1 EA200500406 A1 EA 200500406A1 EA 200500406 A EA200500406 A EA 200500406A EA 200500406 A EA200500406 A EA 200500406A EA 200500406 A1 EA200500406 A1 EA 200500406A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hcv
active inhibitor
serinprotease
acceptable salt
replication
Prior art date
Application number
EA200500406A
Other languages
English (en)
Inventor
Ширлинн Чэнь
Герхард Немиц
Йенс Оливер Грёнлайн
Герхард Штайнманн
Джоселин Абелла Ганн
Пхун До Коста
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA200500406A1 publication Critical patent/EA200500406A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Описаны оральные фармацевтические композиции, наборы и способы лечения и предотвращения вирусного гепатита C (HCV), в которых следующее соединение (1), активный ингибитор серинпротеазы HCV или его фармацевтически приемлемую соль вводят в выбранной области дозировкиТакже описано применение соединения формулы (1) или его фармацевтически приемлемой соли в качестве контрольного вещества для анализа подтверждения репликации HCV, а также в качестве контрольного вещества для определения относительной эффективности одного или нескольких веществ, отдельно или в комбинации, для ингибирования репликации HCV.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200500406A 2002-09-30 2003-09-25 Активный ингибитор серинпротеазы hcv EA200500406A1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41494002P 2002-09-30 2002-09-30
US42190402P 2002-10-29 2002-10-29
US43383402P 2002-12-16 2002-12-16
US44366203P 2003-01-30 2003-01-30
PCT/US2003/030402 WO2004030670A1 (en) 2002-09-30 2003-09-25 Potent inhibitor of hcv serine protease

Publications (1)

Publication Number Publication Date
EA200500406A1 true EA200500406A1 (ru) 2005-12-29

Family

ID=32074646

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200500406A EA200500406A1 (ru) 2002-09-30 2003-09-25 Активный ингибитор серинпротеазы hcv

Country Status (16)

Country Link
US (1) US20040138109A1 (ru)
EP (1) EP1549311A1 (ru)
JP (1) JP2006505618A (ru)
KR (1) KR20050053709A (ru)
CN (1) CN1684683A (ru)
AU (1) AU2003278967A1 (ru)
BR (1) BR0314828A (ru)
CA (1) CA2500259A1 (ru)
CO (1) CO5550459A2 (ru)
EA (1) EA200500406A1 (ru)
EC (1) ECSP055689A (ru)
MX (1) MXPA05003365A (ru)
NO (1) NO20052130L (ru)
PL (1) PL375486A1 (ru)
TW (1) TW200412960A (ru)
WO (1) WO2004030670A1 (ru)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227742B1 (en) 1996-10-18 2012-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
US8241274B2 (en) 2000-01-19 2012-08-14 Medtronic, Inc. Method for guiding a medical device
US7119072B2 (en) * 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US20050075279A1 (en) * 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
UY28240A1 (es) * 2003-03-27 2004-11-08 Boehringer Ingelheim Pharma Fases cristalinas de un potente inhibidor de la hcv
US7176208B2 (en) * 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
MXPA06003141A (es) * 2003-09-22 2006-06-05 Boehringer Ingelheim Int Peptidos macrociclicos activos contra el virus de la hepatitis c.
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
JP2007516239A (ja) 2003-11-20 2007-06-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 特に複分解反応生成物からの、遷移金属の除去方法
JP4682155B2 (ja) * 2004-01-21 2011-05-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎ウイルスに対して活性な大環状ペプチド
EP1909564A4 (en) 2005-07-18 2010-06-30 Novartis Ag SMALL ANIMAL MODEL FOR HCV REPLICATION
SG166791A1 (en) 2005-07-25 2010-12-29 Intermune Inc Novel macrocyclic inhibitors of hepatitis c virus replication
US8076365B2 (en) 2005-08-12 2011-12-13 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
DE602006019323D1 (de) 2005-10-11 2011-02-10 Intermune Inc Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7456165B2 (en) * 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
RU2008152171A (ru) * 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
JP2010500978A (ja) 2006-08-17 2010-01-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼインヒビター
WO2008137779A2 (en) * 2007-05-03 2008-11-13 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
BRPI0811447A2 (pt) * 2007-05-10 2014-10-29 Intermune Inc Compostos, composição farmacêutica e métodos de inibição da atividade da protease ns3/ns4, de tratamento da fibrose hepática e de intensificação da função hepática num indivíduo tendo infecção de vírus da hepatite c.
US8242140B2 (en) 2007-08-03 2012-08-14 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US8419332B2 (en) * 2007-10-19 2013-04-16 Atlas Bolt & Screw Company Llc Non-dimpling fastener
JP5529036B2 (ja) 2007-12-05 2014-06-25 エナンタ ファーマシューティカルズ インコーポレイテッド フッ素化トリペプチドｈｃｖセリンプロテアーゼ阻害剤
AU2008338273B2 (en) 2007-12-19 2014-10-02 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EP2282762A2 (en) 2008-04-15 2011-02-16 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
MX2011007195A (es) 2009-01-07 2013-07-12 Scynexis Inc Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
JP5639155B2 (ja) 2009-05-13 2014-12-10 エナンタ ファーマシューティカルズ インコーポレイテッド Ｃ型肝炎ウイルスインヒビターとしての大環状化合物
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
RS54638B1 (en) 2010-09-21 2016-08-31 Enanta Pharmaceuticals, Inc. HCV SERIN PROTEASE INHIBITORS DERIVED FROM MACROCYCLIC PROLINE
CA2821340A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc. Phenanthridine macrocyclic hepatitis c serine protease inhibitors
WO2012092409A2 (en) 2010-12-30 2012-07-05 Enanta Phararmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors

Also Published As

Publication number Publication date
NO20052130L (no) 2005-04-29
KR20050053709A (ko) 2005-06-08
EP1549311A1 (en) 2005-07-06
MXPA05003365A (es) 2005-06-22
CA2500259A1 (en) 2004-04-15
ECSP055689A (es) 2005-07-06
TW200412960A (en) 2004-08-01
AU2003278967A1 (en) 2004-04-23
US20040138109A1 (en) 2004-07-15
CO5550459A2 (es) 2005-08-31
JP2006505618A (ja) 2006-02-16
BR0314828A (pt) 2005-08-02
PL375486A1 (en) 2005-11-28
CN1684683A (zh) 2005-10-19
WO2004030670A1 (en) 2004-04-15

Similar Documents

Publication Publication Date Title
EA200500406A1 (ru) Активный ингибитор серинпротеазы hcv
EA200201271A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
EA200800413A1 (ru) Новые макроциклические ингибиторы репликации вируса гепатита с
EA200601467A1 (ru) Макроциклические соединения в качестве ингибиторов вирусной репликации
CY1113809T1 (el) Μακροκυκλικα καρβοξυλικα οξεα και ακυλοσουλφοναμιδικες ενωσεις ως αναστολεις της αντιγραφης του hcv
ATE539744T1 (de) Hemmer von serin-protease, insbesondere von hepatitis-c-virus-ns3-ns4a-protease, mit einem kondensierten ringsystem
ATE413411T1 (de) Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
ATE481106T1 (de) Heterocyclische sulfonamid-hepatitis-c-virus- hemmer
EA200701869A1 (ru) Пептидомиметические ингибиторы протеазы
EA200100972A1 (ru) Новые соединения и композиции как ингибиторы протеаз
ES2240446T3 (es) Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c.
EA200000920A1 (ru) Производные бициклических гидроксамовых кислот
EA200300873A1 (ru) Новая соль сукцинат o-десметилвенлафаксина
EA200300776A1 (ru) Производные фенэтаноламина для лечения респираторных заболеваний
EA199800943A1 (ru) Производные мочевины и их применение в качестве ингибиторов инозин-5`-монофосфат- дегидрогеназы
NO20044897L (no) Hepatitt C virus inhibitorer
HUP0400456A2 (hu) Hepatitis C vírus N-ciklikus P2 csoportokat tartalmazó makrociklusos NS3-szerin proteáz inhibitorai és ezeket tartalmazó gyógyszerkészítmények
EA200000759A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
ATE327246T1 (de) Hepatitis c tripeptid inhibitoren
EA200400289A1 (ru) Производные аминоизоксазола, активные в качестве ингибиторов киназы
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
EA200501532A1 (ru) Фармацевтические композиции ингибиторов вирусной протеазы гепатита с
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
EA200300293A1 (ru) Противовоспалительные конденсированные пирролокарбазолы
EA200600227A1 (ru) Замещённые арилтиомочевины, применимые в качестве ингибиторов репликации вирусов